Voyager Therapeutics (NASDAQ:VYGR) Trading Down 1.1%

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s share price dropped 1.1% during mid-day trading on Tuesday . The stock traded as low as $8.07 and last traded at $8.15. Approximately 97,338 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 934,279 shares. The stock had previously closed at $8.24.

Analyst Ratings Changes

VYGR has been the subject of several recent research reports. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. Citigroup initiated coverage on Voyager Therapeutics in a research note on Thursday, March 7th. They issued a “buy” rating and a $16.00 price objective for the company. Wells Fargo & Company raised Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $9.00 to $14.00 in a research note on Tuesday, January 2nd. Guggenheim initiated coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price objective for the company. Finally, HC Wainwright initiated coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

Voyager Therapeutics Stock Performance

The stock has a market capitalization of $436.57 million, a P/E ratio of 2.64 and a beta of 0.96. The business has a fifty day simple moving average of $8.78 and a 200-day simple moving average of $7.95.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The company had revenue of $90.06 million for the quarter, compared to analysts’ expectations of $4.95 million. On average, sell-side analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Voyager Therapeutics

Large investors have recently modified their holdings of the company. Gladius Capital Management LP bought a new position in shares of Voyager Therapeutics in the 3rd quarter worth $25,000. Ameritas Investment Partners Inc. bought a new position in shares of Voyager Therapeutics in the 2nd quarter worth $30,000. UBS Group AG bought a new position in shares of Voyager Therapeutics in the 1st quarter worth $39,000. AJOVista LLC bought a new position in shares of Voyager Therapeutics in the 4th quarter worth $39,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Voyager Therapeutics in the 4th quarter worth $43,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.